期刊
AUTOIMMUNITY REVIEWS
卷 20, 期 7, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.autrev.2021.102846
关键词
CCR6; CCL20; Mucosal tolerance; Regulatory CD4 T cells; Th17 cells
类别
资金
- Department of Biotechnology [BT/PR15533/MED/30/1616/2015, BT/PR14156/BRB/10/1515/2016]
- Department of Science and Technology, Ministry of Science and Technology, Government of India [DST/SJF/LSA-01/2017-18]
CCR6 and CCL20 play crucial roles in cell migration and inflammatory conditions, with strong associations found between their expression and disease severity in various autoimmune disorders. Targeting the CCR6-CCL20 axis shows promise in controlling autoimmune diseases by preventing immune cell migration and reducing inflammation.
Chemokine receptor CCR6 is expressed on various cells such as B cells, immature dendritic cells, innate lymphoid cells (ILCs), regulatory CD4 T cells, and Th17 cells. CCL20 is the only known high-affinity ligand that binds to CCR6 and drives CCR6+ cells' migration in tissues. CCL20 is mainly produced by epithelial cells, and its expression is increased by several folds under inflammatory conditions. Genome-wide association studies (GWAS) in patients with inflammatory bowel disease (IBD), psoriasis (PS), rheumatoid arthritis (RA), and multiple sclerosis (MS) showed a very strong correlation between the expression of CCR6 and disease severity. It has been shown that disruption of CCR6-CCL20 interaction by using antibodies or antagonists prevents the migration of CCR6 expressing immune cells at the site of inflammation and reduces the severity of the disease. This review discussed the importance of the CCR6-CCL20 axis in IBD, PS, RA, and MS, and recent advances in targeting the CCR6-CCL20 in controlling these autoimmune diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据